HIV, a boring thing, that scares us! Not me! 25 years, almost that, and what would I have to complain about now, of having lived little? Laughs!
Powerful HIV antibodies may need the help of a second antibody to develop.
NIAID-funded scientists discover cooperation between antibodies
John R. Mascola, Doctor of Medicine, on the right, led a team at the NIAID Vaccine Research Center that participated in the study.
View larger image.The link is broken and I killed it!
A strategy for developing a highly effective HIV vaccine is to understand how some people infected with the virus naturally develop antibodies that can prevent a large percentage of HIV strains from infecting human cells in the laboratory.
Broadly Neutralizing Antibodies (bNAbs)
These so-called broadly neutralizing antibodies (bNAbs) develop too late to help infected people beat the virus, but if a vaccine could boost the immune system of uninfected people to produce bNAbs, it could protect them from HIV infection.
Researchers have been studying serial blood samples donated by a South African individual with HIV between 15 weeks and 4 years after the infection, in order to understand how his immune system developed a powerful bNAb.
Previously, scientists notesthey discussed how bNAb changed from its initial and immature form to its final and more powerful form - capable of combating HIV - through interactions with the virus for several months.
It All Starts With HIV Infection
In new research, the scientists found that, at the beginning of the infection process, a second, more common antibody, influenced the virus to develop a mutation that would help bNAb to develop its largely neutralizing capacity.
Thus, the antibody-HIV coevolution process may involve more than one antibody, a finding with possible implications for the development of an HIV vaccine.
The new study was led by Barton F. Haynes, MD, director of the Institute of Human Vaccines, Duke University School of Medicine,
And, also, a researcher at the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the United States National Institute of Health (NIH).
The collaborating scientists at the Vaccine Research Center (VRC) were led by John R. Mascola, PhD in Medicine and director of the VRC.
F Gao et al. Cooperation of B-cell lineages in induction of HIV-1 broadly neutralizing antibodies. Cell DOI: 10.1016 / j.cell.2014.06.022 (2014).
Anthony S. Fauci, Doctor of Medicine and director of NIAID, and John R. Mascola, Doctor of Medicine and director of the NIAID Vaccine Research Center, are available for comment.
To schedule interviews, please contact Laura S. Leifman, (301) 402-1663, firstname.lastname@example.org.
â € <
NIAID conducts and funds research - at NIH, throughout the United States and around the world - that aims to study the causes of infectious and autoimmune diseases and develop better ways to prevent, diagnose and treat these diseases. News, newsletters and other NIAID-related materials are available on the institute's website. About the United States National Institute of Health (NIH): NIH, which is the American medical research agency, includes 27 Institutes and Centers and is part of the United States Department of Health and Human Services. NIH is the leading federal agency that conducts and funds basic, clinical and translational medical research. He is investigating the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.